Ensysce Biosciences Inc. Common Stock (ENSC)

About ENSC

Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, develops prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, designed to release clinically effective drugs only when exposed to specific physiological conditions; and Multi-Pill Abuse Resistance (MPAR) platform, an over-do…

Sector

Health Care

Industry

Biotechnology: Pharmaceutical Preparations

Employees

8

Website

www.ensysce.com

Fundamentals

1-day range

$0.473$0.55

Market cap

$8.06M

P/E (trailing)

—

P/E (forward)

-4.73

EPS (trailing)

$-3.11

Dividend yield

—

Beta

0.90

Avg. volume

15.86M

Ensysce Biosciences Inc. Common Stock Competitors

Chosen by industry and closest market cap.

• ENSC

  Ensysce Biosciences Inc. Common Stock

  $0.4

  ▲ 0.25%
  Market cap $8.06MP/E —
  $0.23$2.75
• SNGX

  Soligenix Inc. Common Stock

  $0.38

  ▲ 0.00%
  Market cap $8.24MP/E —
  $0.28$3.22
• APRE

  Aprea Therapeutics Inc. Common stock

  $0.8387

  ▼ 2.48%
  Market cap $7.83MP/E —
  $0.548$1.69
• PCSA

  Processa Pharmaceuticals Inc. Common Stock

  $2.07

  ▼ 1.90%
  Market cap $7.65MP/E 3.31
  $1.67$14.24
• CNSP

  CNS Pharmaceuticals Inc. Common Stock

  $5.52

  ▲ 0.11%
  Market cap $7.65MP/E —
  $1.9$10.59
• XCUR

  Exicure Inc. Common Stock

  $1.34

  ▼ 5.32%
  Market cap $8.60MP/E —
  $1.05$9.48
• MTVA

  MetaVia Inc. Common Stock

  $1.71

  ▲ 3.01%
  Market cap $7.49MP/E —
  $0.9661$19.03

P/E shows — for peers not currently carrying a live signal of their own.

Institutional Ownership

March 31, 2026

Total shares held

463.2K

Total value held

$240.6K

Institutional holders

14